American Society of Hirudotherapy

Effect of taleeq (leech therapy) in dawali (varicose veins)

Nigar Z, Alam MA (2011) · Ancient Science of Life · n=50

RCT evidence detailTrial reference
GRADE Very LowInsufficient evidence
Sample size of this trial compared with other venous-insufficiency trialsFuchs J 1995410Stamenova PK 200160Nigar Z 201150
This trial (highlighted) by sample size alongside other indexed venous-insufficiency trials. Larger trials generally carry more statistical weight.

Study Profile

Design
single-center, open-label, randomized controlled clinical trial (National Institute of Unani Medicine Hospital, Bangalore, India)
Sample size (n)
50
Intervention
Leech therapy (taleeq) applied on alternate days for 2 months (test group, n=30)
Comparator
Grade 2 compression stockings plus limb elevation for 2 months (control group, n=20)
Primary endpoint
Composite of pain/leg discomfort, limb girth at calf/ankle/feet, pigmentation area and colour, assessed every 15 days; hemoglobin monitoring for anaemia; venous anatomy by colour-flow Doppler
Primary result
Test group: significant reduction in pain, limb girth, pigmentation, and number of perforators (within-group p-values significant); control group: significant reduction in pain and limb girth only with no pigmentation improvement; neither group showed significant change in saphenofemoral or saphenopopliteal junction incompetency
Follow-up duration
60 days

Key Findings

  • First randomized clinical trial of leech therapy (taleeq) for varicose veins (dawali) in the Unani medicine tradition
  • Multi-endpoint improvement in pain, limb girth, pigmentation, and perforator count favored leech arm over compression stockings
  • Neither modality altered underlying saphenofemoral or saphenopopliteal junction incompetency - effect is symptomatic only
  • Authors recommended leech therapy be combined with compression and lifestyle modification for optimal varicose vein management
  • Conducted within a Unani regimental therapy framework with conceptual basis in humoural theory (saudavi madda, balgham ghaleez)

Limitations

  • Unequal group sizes (n=30 test vs n=20 control) raise selection-bias risk
  • Open-label design with unblinded outcome assessment
  • Composite endpoints not statistically pre-specified or hierarchically tested
  • Single Indian Unani institution - generalizability to Western venous-disease populations untested
  • No quantitative reflux velocity, venous filling index, or CEAP classification reported

Clinical Implications

Nigar 2011 is the most-cited Indian Unani RCT on leech therapy for chronic venous insufficiency. Its primary value is documentation of a symptom-based regimental therapy framework that integrates leeching with compression and lifestyle modification. The trial does not support leech therapy as a primary treatment for advanced venous disease (no effect on junction incompetency) but does support symptomatic-relief use in patients seeking traditional-medicine approaches. For Western clinicians, Nigar 2011 illustrates how leech therapy is positioned within the wider Unani treatment philosophy rather than as a standalone intervention, and should be interpreted in that conceptual context.

Related Trials

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.